PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042545
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042545
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market size was valued at US$ 2,341.82 Million in 2025, expanding at a CAGR of 8.30% from 2026 to 2033.
An Endoscopic Retrograde Cholangiopancreatography (ERCP) is a medical process that is used to observe and manage circumstances affecting the bile ducts and pancreas in a minimally invasive way. In this method, a thin, flexible tube is passed via mouth into the small intestine, allowing doctors to approach internal ducts. With the provision of imaging, they can detect blockages or abnormalities and provide treatment at the same time. It is mainly used for treatment rather than routine diagnosis. The ERCP-related healthcare area is shaped by the problem of digestive and pancreatic diseases and the increasing need for minimally invasive care globally. Organizations like the World Health Organization emphasize that gastrointestinal illnesses contribute to an important share of global disease burden, growing the need for interventional care. The National Institute of Diabetes and Digestive and Kidney Diseases reports that gallstones affect over 20 million individuals in the United States, often requiring ductal procedures. Moreover, the National Cancer Institute records tens of thousands of pancreatic cancer cases annually, many linked with bile duct complications.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market- Market Dynamics
Advancements in endoscopy technology and clinical capability
Continuous development in imaging and device design is enhancing the efficiency and safety of ERCP measures as they directly advance how safely and effectively the procedure can be completed. Advanced endoscopic systems now deliver clearer imaging, better navigation inside delicate ducts, and more precise control during treatment. This allows doctors to recognize problems more accurately and carry out procedures like stone removal or stent placement with reduced procedural difficulty. The European Medicines Agency supports the approval of advanced endoscopic devices, ensuring that safer and more effective technologies reach healthcare systems. The Health Canada also oversees the regulation of modern medical imaging and endoscopic tools, encouraging innovation in minimally invasive care.
In same way, the Ministry of Health, Labour and Welfare also encourages the acceptance of advanced medical skills in clinical practice, firming procedural capability in hospitals. From a business outlook, Stryker Corporation has reported significant global revenue supported by its medical device portfolio, including imaging solutions. Also, Hoya Corporation, through its endoscopy division, continues to generate substantial healthcare-related revenue.
The Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market is segmented on the basis of Product, Application, Procedure, Technology, End User, and Region.
Based on product classification, the market varies into four kinds, i.e., endotherapy, endoscopes, energy devices, and visualization. The endoscopes are likely to remain an important element due to their essential role in both diagnosis and treatment. These devices act as the key access tool, letting physicians reach the bile and pancreatic ducts, visualize internal structures, and guide all therapeutic actions. As clinical demand moves toward precise and minimally invasive interventions, the need for high-quality imaging and flexible scope design continues to support steady use of this product type across hospitals and specialty centers. From the business side, Boston Scientific reports strong and sustained revenue contribution from its endoscopy-related portfolio, reflecting continued procedural reliance on advanced scopes. Similarly, Fujifilm Holdings has highlighted significant growth in its medical systems division, particularly in endoscopic imaging technologies used in gastrointestinal care.
Among two types of procedures: therapeutic and diagnostic. The therapeutic indicates a considerable share of clinical usage because modern practice has shifted from diagnosis to active treatment. Doctors now use ERCP more often to solve problems quickly, such as removing bile duct stones, relieving blockages, or placing stents, rather than only classifying conditions. This shift is mainly supported by the availability of better imaging techniques outside ERCP, which has reduced its diagnostic role. Participants like, Cook Medical report consistent global utilization of its ERCP accessory devices, particularly those used for stone extraction and stent placement, reflecting steady therapeutic procedure demand. Similarly, Olympus Corporation highlights strong demand for its therapeutic endoscopy platforms, which are widely used in interventional gastrointestinal procedures.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market- Geographical Insights
Within global healthcare procedures, the outlines in ERCP sector reveal how digestive disorders and medical infrastructure advance together, with the Asia-Pacific region drawing specific attention due to its large patient base and increasing clinical capacity. In this region, government-linked observations focus on a meaningful disease problem: a survey published by the National Center for Biotechnology Information reported chronic pancreatitis incidence reaching 114-200 per 100,000 people in parts of India, signifying substantial clinical need for duct-related interventions like ERCP. In China, national-level disease tracking referenced in public health literature shows pancreatitis cases rising from 380,018 in 1990 to 493,765 in 2019, reflecting growing procedural demand in hospital settings. Moreover, clinical direction from National Institutes of Health focuses on gallstones as a foremost cause of pancreatitis, a condition widely detected across Asian populations and often needing ERCP-based management.
Within this region, Japan shows an organized and clinically developed environment for ERCP measures, maintained by detailed government-linked healthcare data and solid domestic medical technology involvement. Evidence from the nationwide Diagnosis Procedure Combination database, referenced through the National Center for Biotechnology Information, shows that over 1,073,513 ERCP procedures were recorded between 2016 and 2023, reflecting widespread clinical adoption in hospitals. Alongside this, a nationwide epidemiological survey backed by the Ministry of Health, Labour and Welfare of Japan estimated 78,450 acute pancreatitis patients in 2016, reflecting a sizeable population requiring pancreatic and biliary interventions. Firms like; Olympus Corporation support this ecosystem through ongoing development of endoscopy devices used in ERCP procedures.
U.S. Endoscopic Retrograde Cholangiopancreatography (ERCP) Market- Country Insights
In the United States, the use of ERCP displays a well-established clinical system supported by public health data and medical innovation. The procedure is commonly carried out in advanced hospital settings where trained specialists manage conditions related to the bile ducts and pancreas. For example, the National Institute of Diabetes and Digestive and Kidney Diseases notes that gallstones affect nearly 25 million people in the country, many of whom may require bile duct procedures such as ERCP. The Centers for Disease Control and Prevention also reports over 300,000 hospital admissions each year linked to gallstone disease, indicating steady procedural demand. Additionally, the National Cancer Institute records about 64,000 new pancreatic cancer cases annually, where ERCP may support diagnosis and care. From an industry view, Boston Scientific Corporation generated around 14 billion USD in revenue, supported by its endoscopy portfolio. Cook Medical maintains a broad ERCP accessory portfolio, with global distribution supporting consistent procedural supply.
In response to rising growth in demand for minimally invasive gastrointestinal measures, the atmosphere around ERCP devices and services is formed by a combination of global manufacturers and medical technology firms. Companies like Fujifilm Holdings Corporation, Medtronic plc, Cook Medical, Boston Scientific Corporation, and Karl Storz SE & Co. KG contribute through product revolution, physician training, and distribution partnerships. These firms focus on enhancing visualization systems, device precision, and procedural safety while conserving their supply networks through hospitals and specialty centers. For example, Medtronic plc expanded its gastrointestinal portfolio with advanced endoscopic tools designed to support complex biliary procedures. Similarly, Fujifilm Holdings Corporation strengthened its endoscopy solutions with upgraded imaging technologies aimed at enhancing clinical clarity. These developments exhibit a measured move to safer, more efficient practices, supporting sustained implementation in modern healthcare surroundings.
In March 2025, Olympus Corporation introduced an updated duodenoscope with enhanced imaging and disposable components to support infection control during ERCP procedures. The initiative aligns with evolving regulatory expectations on endoscope safety. The updated duodenoscope supports safer ERCP procedures by improving infection control while aligning with evolving regulatory expectations on device safety.
In January 2025, Boston Scientific Corporation expanded its endoscopy portfolio through new ERCP-compatible stent systems designed to assist in managing biliary strictures with improved placement precision. The expansion supports improved ERCP procedures, enabling precise stent placement and enhancing treatment outcomes for patients with biliary strictures.